BG103861A - 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds - Google Patents

6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Info

Publication number
BG103861A
BG103861A BG103861A BG10386199A BG103861A BG 103861 A BG103861 A BG 103861A BG 103861 A BG103861 A BG 103861A BG 10386199 A BG10386199 A BG 10386199A BG 103861 A BG103861 A BG 103861A
Authority
BG
Bulgaria
Prior art keywords
aminopyrido
disubstituted
compounds
pyrimidine compounds
therapeutically effective
Prior art date
Application number
BG103861A
Other languages
Bulgarian (bg)
Inventor
Shripad Bhagwat
Chih-Hung Lee
Richard Perner
Ya-Gui Gu
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG103861A publication Critical patent/BG103861A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The compounds have the formula where R1, R2, R3 & R4 are variants and are selected from the groups including alkyl, aryl, heteoraryl and heterocycle and their substituted variants. The invention also relates to a method for the adenosinekinase inhibition by the applications including a therapeutically effective quantity of them in combination with a pharmaceutically acceptable carrier. The invention also relates to a method for the treatment of cerebral ischaemia, epilepsy, pain, inflammation and sepsis in mammals where therapeutically effective quantity of the compounds is applied, and to methods for their preparation. 18 claims
BG103861A 1997-04-16 1999-11-05 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds BG103861A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83439397A 1997-04-16 1997-04-16
PCT/US1998/004127 WO1998046603A1 (en) 1997-04-16 1998-04-16 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
BG103861A true BG103861A (en) 2000-06-30

Family

ID=25266829

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103861A BG103861A (en) 1997-04-16 1999-11-05 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds

Country Status (20)

Country Link
EP (1) EP0979230A1 (en)
JP (1) JP2001520649A (en)
KR (1) KR20010006453A (en)
CN (1) CN1259948A (en)
AR (1) AR012435A1 (en)
AU (1) AU744528B2 (en)
BG (1) BG103861A (en)
BR (1) BR9809088A (en)
CA (1) CA2287465A1 (en)
CO (1) CO4940439A1 (en)
HU (1) HUP0001402A3 (en)
IL (1) IL131892A0 (en)
NO (1) NO995033L (en)
NZ (1) NZ337844A (en)
PL (1) PL336262A1 (en)
SK (1) SK142099A3 (en)
TR (1) TR199902456T2 (en)
TW (1) TW458977B (en)
WO (1) WO1998046603A1 (en)
ZA (1) ZA982912B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
BRPI0207172B8 (en) * 2001-02-12 2021-05-25 Hoffmann La Roche 6-substituted pyrido-pyrimidines, their composition and use, as well as their intermediate
EP1824861A2 (en) 2004-11-12 2007-08-29 Trustees of the Tufts College Lipase inhibitors
WO2008121257A1 (en) * 2007-03-28 2008-10-09 Merck & Co., Inc. Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
EA201590693A1 (en) * 2012-10-05 2015-08-31 Ригель Фармасьютикалс, Инк. INHIBITORS GDF-8
WO2017205848A1 (en) * 2016-05-27 2017-11-30 Legacy Emanuel Hospital & Health Center Methanocarba derivatives of pseudoribose that inhibit adenosine kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
TR199902456T2 (en) 2000-07-21
NO995033L (en) 1999-12-15
KR20010006453A (en) 2001-01-26
WO1998046603A1 (en) 1998-10-22
ZA982912B (en) 1998-10-09
PL336262A1 (en) 2000-06-19
TW458977B (en) 2001-10-11
CN1259948A (en) 2000-07-12
CO4940439A1 (en) 2000-07-24
EP0979230A1 (en) 2000-02-16
NZ337844A (en) 2001-11-30
HUP0001402A3 (en) 2001-01-29
AU7098198A (en) 1998-11-11
AU744528B2 (en) 2002-02-28
HUP0001402A2 (en) 2000-10-28
CA2287465A1 (en) 1998-10-22
NO995033D0 (en) 1999-10-15
SK142099A3 (en) 2000-05-16
JP2001520649A (en) 2001-10-30
BR9809088A (en) 2000-08-01
IL131892A0 (en) 2001-03-19
AR012435A1 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
MY121606A (en) Naphthalene derivatives, process for the preparation thereof, and intermediates therefor and pharmaceutical compositions comprising them
TR200000837A2 (en) Process and intermediates to prepare anti-cancer compositions.
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
ES8706684A1 (en) Carbapenem compounds and production thereof.
PL315193A1 (en) Diazabicyclic antagonists of neurokinin
CA2401229A1 (en) Aryl fused azapolycyclic compounds
CA2216129A1 (en) Lactam-containing hydroxamic acids
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
TW372237B (en) 1-2-4 triazolo[1,5-a]pyrimidines, pharmaceutical compositions containing them for treatment and/or prophylaxis of seizures, neurological disorders and/or conditions in which there is neurological damage, and processes for their preparation
MX9701819A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents.
BG103842A (en) 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors
BG104983A (en) Aryl fused azapolycyclic compounds
BG103861A (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
BG103853A (en) 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds
WO2002044191A3 (en) Anti-inflammatory compounds derived from pseudopterogorgia elisabethae
NZ222045A (en) From diamides up to tetrapeptides for use as anticanvulsants
AU2001276200A1 (en) Compounds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated diseases or dysfunction
MXPA98005355A (en) 5-[(heteroaryl) alkyl]-3 -oxo-pyrido [1, 2-a] benzimidazole -4-carboxamide derivatives useful in treating central nervous system disorders.
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
IL116382A0 (en) Trisubstituted t hoxanthines and pharmaceutical compositions containing the same
AU3479299A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
BG103985A (en) Multicyclic derivatives of erythromycin